Regeneron enters amended deal with Sanofi for full rights to Libtayo; pays $900M upfront

REGENERON PHARMACEUTICALS, INC.

Regeneron gains sole worldwide rights to develop and commercialize Libtayo, effective upon regulatory approvals.
Regeneron will pay Sanofi $900M upfront within 10 business days of effective date.
Regeneron will pay an 11% royalty on Libtayo net sales through March 2034, plus up to $200M in milestone payments.
Development cost reimbursement rate under Antibody LCA increased from 10% to 20% effective April 1, 2022.
Transition services, distribution, and manufacturing agreements support the handover from Sanofi.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.